In the Specification

Please replace paragraph [0001] on page 1 of the specification with the following paragraph:

[0001] ~~This application~~ This application is the National Stage of International Application Number PCT/US2004/010353, filed April 2, 2004, which claims benefit of priority under 35 U.S.C. §119(e)(1) to U.S. Provisional Patent Application No. 60/459,939, filed April 2, 2003 (each of which is hereby incorporated by reference in its entirety). The present application also is a continuation-in-part of U.S. Patent Application No. 10/103,395, filed March 20, 2002, which is a ~~continuation-in-part~~ continuation of U.S. Patent Application No. 09/009,953, filed January 21, 1998, now U.S. Patent No. 6,413,517, issued July 2, 2002, which claims benefit of priority under 35 U.S.C. § 119(e)(1) to U.S. Provisional Patent Application Nos. 60/036,713, filed January 23, 1997 and 60/037,432 filed February 7, 1997, each of which is incorporated herein by reference in its entirety, including all amino acid and/or polynucleotide sequences, sequence listings, figures, claims, and tables.

Please replace paragraph [00170] on page 63 of the specification with the following paragraph:

[00170] For the present study, peptides were derived from the amino acid sequences of salmon calcitonin (amino acids 83-114 of P01263) (SEQ ID NO:4), human erythropoietin (amino acids 28-193 of P01588) (SEQ ID NO:3), human growth hormone 1 isoform 1 (amino acids 27-217 of P01241) (SEQ ID NO:5), human insulin alpha (amino acids 90-110 of P01308) (SEQ ID NO:6), human insulin beta (amino acids 25-54 of P01308) (SEQ ID NO:7), and human interferon beta (amino acids 22-187 of AAC41702) (SEQ ID NO:8) ~~[see Figure 11]~~.

Please replace paragraph [00253] on page 102 of the specification with the following paragraph:

[00253] To confirm that the EPO epitope analogs with disrupted HLA-DR binding affinity were less immunogenic, we utilized PBMC from 5 donors that had responded previously wild-type EPO and against the wild type EPO epitopes EPO 101 and EPO 136 and tested peptide combinations using the primary *in vitro* immunogenicity assay. In each case, we included one analog from the EPO 101 epitope, and one from of the EPO 136 epitope. These peptides were

pooled in equimolar concentrations and tested; the wild-type epitopes EPO 101 and EPO 136 were also pooled at equimolar concentrations and used as positive controls. For each combination, the magnitude of responses net SFC and frequency of response in 10 individual cultures from each donor were recorded. ~~The data obtained are shown in Figure 12.~~ Immunogenicity of the two wild-type EPO epitopes (EPO 101-115 and EPO 136-150) in the form of synthetic peptides, or EPO epitope analog combinations C2 (L102P and S146D), C3 (T107D and S146D) C4 (L102G, T107D and S146D) and C5 (L102S, T107D and S146D) were tested in primary *in vitro* induction assays. Ten individual cultures each from five different donors were tested.

Please delete paragraphs [0039] and [0040] on page 14 of the specification.

After page 137: Please insert as new page 138 the attached Abstract of the Disclosure.